drugset / Trial / NCT03902002

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT03902002

Phase 1 Completed 48 enrolled Biogen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will examine the pharmacokinetics (PK) of omaveloxolone following a single oral dose of omaveloxolone in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.

Timeline

Start
2019-07-19
Primary completion
2020-01-27
Completion
2020-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Omaveloxolone Small molecule 150 mg Oral

Indications

No indication recorded.